Anand Mehra Biography and Net Worth

Director of Aclaris Therapeutics

Anand Mehra has served as a member of Aclaris’ board of directors since 2014. Dr. Mehra has served as a founding partner of Forge Life Science Partners, a biotech investment firm, since its inception in May 2023. Prior to founding Forge, Dr. Mehra served mostly recently as a managing general partner of Sofinnova Investments, Inc. (fka Sofinnova Ventures, Inc.), a biotech investment firm from 2007 to January 2020. Prior to joining Sofinnova, Dr. Mehra worked in J.P. Morgan’s private equity and venture capital group, and before that, Dr. Mehra was a consultant in McKinsey & Company’s pharmaceutical practice. Dr. Mehra currently serves as the chair of the board of directors of the publicly held company Merus N.V. He previously served on the board of directors of the pharmaceutical company Spark Therapeutics, Inc. Dr. Mehra received a Bachelor of Arts degree in political philosophy from the University of Virginia and a Doctor of Medicine from Columbia University’s College of Physicians and Surgeons.

What is Anand Mehra's net worth?: The estimated net worth of Anand Mehra is at least $2.54 million as of November 19th, 2024. Mehra owns 710,030 shares of Aclaris Therapeutics stock worth more than $2,538,357 as of March 27th. This net worth estimate does not reflect any other assets that Mehra may own. Learn More about Anand Mehra's net worth.
How do I contact Anand Mehra?: The corporate mailing address for Mehra and other Aclaris Therapeutics executives is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. Aclaris Therapeutics can also be reached via phone at (484) 324-7933 and via email at [email protected]. Learn More on Anand Mehra's contact information.
Has Anand Mehra been buying or selling shares of Aclaris Therapeutics?: Anand Mehra has not been actively trading shares of Aclaris Therapeutics during the last quarter. Most recently, on Tuesday, November 19th, Anand Mehra bought 666,666 shares of Aclaris Therapeutics stock. The stock was acquired at an average cost of $2.25 per share, with a total value of $1,499,998.50. Following the completion of the transaction, the director now directly owns 710,030 shares of the company's stock, valued at $1,597,567.50. Learn More on Anand Mehra's trading history.
Who are Aclaris Therapeutics' active insiders?: Aclaris Therapeutics' insider roster includes Kamil Ali-Jackson (Insider), David Gordon (Insider), Anand Mehra (Director), Joseph Monahan (Insider), Frank Ruffo (CFO), and Neal Walker (CEO). Learn More on Aclaris Therapeutics' active insiders.

Anand Mehra Insider Trading History at Aclaris Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/19/2024	Buy	666,666	$2.25	$1,499,998.50	710,030
10/22/2018	Buy	372,093	$10.75	$3,999,999.75
1/10/2017	Sell	750,000	$28.25	$21,187,500.00

Anand Mehra Buying and Selling Activity at Aclaris Therapeutics

Aclaris Therapeutics Company Overview

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Today's Range

Now: $3.52

$3.40

$3.61

50 Day Range

MA: $3.48

$2.62

$4.53

2 Week Range

Now: $3.52

$1.05

$4.89

Volume

2,387,968 shs

Average Volume

2,423,745 shs

Market Capitalization

$424.51 million

P/E Ratio

N/A

Dividend Yield